Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

BACKGROUND AND AIMS: In the UK, treatments for patients with moderately to severely active ulcerative colitis who have an inadequate response to conventional therapies comprise four biological therapies—the tumour necrosis factor inhibitor (TNFi) agents adalimumab, golimumab and infliximab and the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohan, Christoph, Diamantopoulos, Alex, LeReun, Corinne, Wright, Emily, Bohm, Natalie, Sawyer, Laura Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6673763/
https://www.ncbi.nlm.nih.gov/pubmed/31413856
http://dx.doi.org/10.1136/bmjgast-2019-000302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6673763/
https://www.ncbi.nlm.nih.gov/pubmed/31413856
http://dx.doi.org/10.1136/bmjgast-2019-000302

Ejemplares similares